Coriolis is a globally operating service provider and one of the world leaders in formulation research and development of (bio)pharmaceutical drugs and vaccines.

As a privately held and independent company with an interdisciplinary team of highly skilled scientists and an expert scientific advisory board, we provide cutting-edge services and tailor-made solutions for our clients.

We offer a large selection of services for all types of biopharmaceuticals, including proteins, peptides, peptides, nucleic acids, gene- and cell therapy products, vaccines and virus(-like) particles up to biosafety level S2.

Formulation research and development
    (from pre-formulation to market formulations)

Analytical method development
    (aggregate and particle characterization, protein analytics, GMP analytics)

Forced degradation and stability testing
    (stress conditions tailored for the product, stability testing according ICH)

Lyophilization
    (cycle development, scale up, modern PAT-tools)

Supply of pre-clinical material
    (GMP-like conditions in clean room)


Pharmaceutical

Biotechnology

Coriolis Pharma

Silvia Steyrer-Gruber

Frank Schaubhut

Andrea Hawe

The Scientific Research and Development team at Coriolis Pharma focuses on advancing the formulation and analytical methodologies for a diverse range of (bio)pharmaceuticals, including vaccines and gene therapies. This interdisciplinary group develops tailored solutions through rigorous research, stability testing, and innovative lyophilization techniques, ensuring high-quality drug product development while adhering to industry regulations. Their expertise supports the entire process from pre-formulation to the supply of pre-clinical materials in GMP-like conditions.

Scientific Research and Development

About

Team members

Other teams at Coriolis Pharma

Project Management

Leadership Team